Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely Lower Cholesterol and Triglycerides
One-time infusion of investigational CRISPR-Cas9 therapy found to safely reduce LDL cholesterol by 50% and triglycerides by about 55% in Phase 1 trial
Read more
